Aarti Drugs liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.16×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.59×	1.59×	1.60×	1.66×	1.60×
1.06×	1.06×	1.03×	1.05×	1.05×
7.3	7.3	4.6	6.7	9.0
546	546	501	525	559

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health

₹ CrorePeersALIVUS AARTIPHARM ADVENZYMES AGARWALEYE AKUMS APLLTD CORONA HCGMcap ₹4,098 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.16
Current Ratio	1.60	1.66	1.60	1.59	1.59
Quick Ratio	1.05	1.05	1.03	1.06	1.06
Cash, Equiv & ST Investments	9.0	6.7	4.6	7.3	7.3
Working Capital	559.4	525.2	501.4	545.5	545.5

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.